Product for Out-Licensing
- Overview
- Product Profile
Diffucaps® Diltiazem (once-daily)
Diffucaps® Diltiazem is a once-daily hypertension treatment that uses
Eurand’s proprietary Diffucaps sustained-release technology.
The convenience of once-daily dosing can facilitate patient treatment compliance.1 Eurand’s once-daily Diltiazem formulation is appropriate for use in chronic therapy, in which patient convenience and compliance are especially important.
Therapeutic Category |
Cardiovascular |
Indication |
Hypertension |
Development Status |
Commercialized; Licensing opportunities available |
Available Dosage |
|
Product Description |
Once-daily sustained-release capsule |
Eurand Technology |
Diffucaps® - Customized Drug Release technology |
Licensing Opportunities |
Eurand is seeking licensing partners for global opportunities. |
This information is provided solely for the purpose of the evaluation of business opportunities by potential collaboration partners. The information is based on currently existing data and marketing authorizations in a number of jurisdictions and should not be assumed to be approved by regulatory authorities in any individual country. Consumers should consult with their individual physician for product information and should not rely upon any information provided here.
For more information on this product, please contact Eurand.
1 Kardas P. Comparison of patient compliance with once-daily and twice-daily antibiotic regimens in respiratory tract infections: results of a randomized trial. J Antimicrob Chemother. 2007;59:531-536.
Contact Us
Click here to request moreinformation on Eurand's
Products for Out-Licensing